Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1

Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults

Published:2013-08-01 Issue:4 Volume:63 Page:449-455
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Ruane Peter J.,DeJesus Edwin,Berger Daniel,Markowitz Martin,Bredeek U. Fritz,Callebaut Christian,Zhong Lijie,Ramanathan Srini,S. Rhee Martin,Fordyce Marshall W.,Yale Kitty

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference10 articles.

1. Premature aging and premature age-related comorbidities in HIV-infected patients: facts and hypotheses.;Capeau;Clin Infect Dis,2011

2. . Estimated HIV incidence in the United States, 2006-2009.;Prejean;PLoS One,2011

3. Factors affecting adherence to antiretroviral therapy.;Chesney;Clin Infect Dis,2000

4. . Activation of 9-(R)-2-(S)-(S)-1-(isopropoxycarbonyl)ethylamino phenoxyphosphinyl-methoxypropyladenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases.;Birkus;Mol Pharmacol,2008

5. . Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue.;Lee;Antimicrob Agents Chemother,2005

Cited by 274 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HIV Pre-Exposure Prophylaxis;Infectious Disease Clinics of North America;2024-09

2. Plasma, intracellular and lymph node antiretroviral concentrations and HIV DNA change during primary HIV infection: Results from the INACTION P25 study;International Journal of Antimicrobial Agents;2024-08

3. Systemic delivery of bictegravir and tenofovir alafenamide using dissolving microneedles for HIV preexposure prophylaxis;International Journal of Pharmaceutics;2024-07

4. Renal safety of tenofovir alafenamide-based antiretroviral therapy in people with HIV: A mini-review;BioScience Trends;2024-04-30

5. Studying the Changes in Physical Functioning and Oxidative Stress-Related Molecules in People Living with HIV after Switching from Triple to Dual Therapy;Antioxidants;2024-04-26